MIRA Pharmaceuticals (MIRA) Quick Liquidity Indicator

The available price action vector for MIRA Pharmaceuticals (MIRA) demonstrates metrics at the level of 202.65. The biotech firm develops synthetic cannabinoid substitutes to combat anxiety and neurological pathologies. Current capital is based on investments in the development of safe treatments for neuropathic pain. The company is currently focused on the scientific battle for patents, which shields it from direct price competition in the commercial market.

mirapharmaceuticals.com (MIRA) - Critical Liquidity Ratio from 02/21/2024 to 10/29/2026

MIRA Pharmaceuticals (MIRA) - metric breakdowns and financial figures

- market value and analyst target forecast:

Price Chart mirapharmaceuticals.com|MIRA - Average Forecast Price

- market capitalization details:

Market Valuation MIRA Pharma|MIRA - Value Adjusted for Debt and Cash

- book capitalization indicators:

Book Value per Share MIRA Pharmaceuticals|MIRA - Net Asset Value|Market Capitalization to Book Value Ratio mirapharmaceuticals.com|MIRA - Company Total Assets

- business debt structure and liquidity details:

- earnings and valuation multiples indicators:

MIRA - Final Profit

Basic company analysis:MIRA Pharmaceuticals

Manufactured product of mirapharmaceuticals.com

Quick liquidity measures a company's ability to instantaneously settle short-term obligations using only cash and accounts receivable, excluding low-liquidity inventories. An acid-test liquidity analysis allows for an assessment of the financial stability of MIRA Pharmaceuticals (MIRA) amidst a high burn rate and early-stage drug development risks, revealing the actual capital cushion available before the commencement of clinical trials.

Main competitors